Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

• Published in: Journal of clinical & translational endocrinology Vol. 30; p. 100306
• Main Authors: Notemi, Léonie Makuété, Amoura, Lamia, Fall Mostaine, Fatéma, Meyer, Laurent, Paris, Dominique, Talha, Samy, Pottecher, Julien, Kessler, Laurence
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.12.2022; Elsevier
• Subjects: Continuous glucose monitoring; Hypoglycemia; Insulin pump therapy; Original Research; Predictive low-glucose management; Continuous glucose monitoring; Insulin pump therapy; CRA; RN; Hypoglycemia; Predictive low-glucose management
• DOI: 10.1016/j.jcte.2022.100306
• ISSN: 2214-6237

•Real-life effectiveness of sensor-augmented pump therapy with predictive low-glucose management (SAP-PGLM) over a 3-years period in 62 patients with type 1 diabetes (T1D)•Interest to combine SAP-PGLM with telemedicine to achieve good and sustainable real-life therapeutic adherence in T1D patients.•Reduction of hypoglycemia and improvement in HbA1c in T1D patients with SAP-PGLM under real-life conditions. Evaluate the efficacy of a new modality of insulin therapy associating both the sensor-augmented pump therapy with predictive low-glucose management (SAP-PLGM) and a telemedicine follow-up in patients with Type 1 diabetes (T1D) in a real-life setting. T1D adults under Minimed 640G system with a telemedicine follow-up for glucose management were included in a retrospective study. The primary endpoint was HbA1c while continuous glucose monitoring parameters (CGM) and treatment compliance were the secondary endpoints. These parameters were analyzed according to the therapeutic indication, HbA1c ≥ 8 % (GroupA) or severe hypoglycemic events (GroupB) and in patients switched to SAP-PLGM therapy. 62patients were analyzed with a 28 ± 12 months of follow-up. In GroupA, HbA1c decreased from 8.3 ± 0.4 % to 7.7 ± 0.7 % (p < 0.05) and to 7.9 ± 0.3 % (p < 0.05) after 2 and 3 years, respectively. In patients switched to SAP-PLGM therapy, HbA1c decreased from 7.7 ± 0.7 % to 7.2 ± 0.8 % (p < 0.05) at 2 years. After 6 months, the time-below-range (<70 mg/dL) decreased from 2.1 % [0.6–4] to 1.1 % [0.3–2.6] (p < 0.05). Severe hypoglycemic events decreased from 1.62 to 0.5events/patient/year in GroupB (p < 0.05). At 3 years, treatment compliance was 92 % [70–97] in the total population. Long-term real-life treatment with the SAP-PLGM therapy combined with telemedicine was associated with improved glycemic control in T1D, along with high treatment compliance.